A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

A recent opinion paper concluded that timely revascularization and dual antiplatelet therapy (DAPT) are crucial in the ...

The actor James Van Der Beek, known for Dawson’s Creek, revealed at the end of 2024, when he was 47, that he’d been diagnosed ...

Contemporary cardiology faces a paradox: unprecedented technological capability coincides with declining scientific curiosity ...

Objective Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the ...

New treatments, care gaps, and cardiac monitoring were major focuses in cardiovascular news this year. The top cardiovascular ...

Abbott has announced the company has received approval from the U.S. Food and Drug Administration (FDA) for its Volt PFA ...

The Cardiac Electrophysiology Department at Al Qassimi Hospital in Sharjah, which is part of the Emirates Health Services, has proudly carried out its first successful treatment for atrial ...

Abbott’s Volt pulsed field ablation system — for the treatment of atrial fibrillation. The Volt system delivers high-energy electrical pulses to targeted areas of the heart to disrupt abnormal rhythms ...

After approval in late 2024, Johnson & Johnson's Varipulse PFA system started 2025 on the wrong foot: Its early rollout had ...

Background Despite anticoagulation, patients with atrial fibrillation (AF) experience persistent elevated cardiovascular risk ...

Introduction Atrial fibrillation (AF) is the leading cause of cardioembolic stroke and is associated with increased stroke severity and fatality. Early identification of AF is essential for adequate ...